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Human primary endothelial cells 
are impaired in nucleotide excision 
repair and sensitive to benzo[a]
pyrene compared with smooth 
muscle cells and pericytes
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Kathrin Laarmann4, Gerhard fritz4 & Bernd Kaina1
the endothelium represents the inner cell layer of blood vessels and is supported by smooth muscle 
cells and pericytes, which form the vessel structure. the endothelium is involved in the pathogenesis 
of many diseases, including the development of atherosclerosis. Due to direct blood contact, the blood 
vessel endothelium is inevitably exposed to genotoxic substances that are systemically taken up by 
the body, including benzo[a]pyrene, which is a major genotoxic component in cigarette smoke and a 
common environmental mutagen and human carcinogen. Here, we evaluated the impact of benzo[a]
pyrene diol epoxide (BpDe), which is the reactive metabolite of benzo[a]pyrene, on the three innermost 
vessel cell types. primary human endothelial cells (HUVec), primary human smooth muscle cells 
(HUASMc) and primary human pericytes (Hpc) were treated with BpDe, and analyses of cytotoxicity, 
cellular senescence and genotoxic effects were then performed. The results showed that HUVEC were 
more sensitive to the cytotoxic activity of BpDe than HUASMc and Hpc. We further show that HUVec 
display a detraction in the repair of BpDe-induced adducts, as determined through the comet assay and 
the quantification of BPDE adducts in post-labelling experiments. A screening for DNA repair factors 
revealed that the nucleotide excision repair (NER) proteins ERCC1, XPF and ligase I were expressed 
at lower levels in HUVec compared with HUASMc and Hpc, which corresponds with the impaired 
neR-mediated removal of BpDe adducts from DnA. taken together, the data revealed that HUVec 
exhibit an unexpected DnA repair-impaired phenotype, which has implications on the response of the 
endothelium to genotoxicants that induce bulky DnA lesions, including the development of vascular 
diseases resulting from smoking and environmental pollution.
The inner layer of blood vessels is lined with more than 10 billion endothelial cells, which regulate, among other 
features, coagulation and blood pressure and play an important role in wound healing1. Smooth muscle cells, 
which surround the larger vessel structures, directly interact with the endothelium and are connected with it 
through a complex signalling system. Together with pericytes, endothelial cells and smooth muscle cells are 
essential for angiogenesis2–4. Pericytes are mainly found on capillaries and post-capillary venules, where they are 
in direct cell-cell contact with the endothelial cell layer5,6. Based on the structure of blood vessels, it is reasonable 
to hypothesize that endothelial cells are primarily exposed to genotoxins that enter the blood stream and could 
thus be considered the first target of endogenous and exogenous systemically available DNA-damaging agents. 
Indeed, genotoxic agents, regardless of whether they are of endogenous or exogenous origin, target the endothe-
lium, as demonstrated by the finding of DNA adducts in atherosclerotic lesions7. Furthermore, the level of geno-
toxic damage has been demonstrated to be predictive for patient’s survival8.
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The genotoxic metabolite benzo[a]pyrene-7R,8S-dihydrodiol-9S,10R-epoxide (BPDE) is the active form of the 
widely distributed polycyclic aromatic hydrocarbon benzo[a]pyrene (B[a]P), which is found in tobacco smoke, 
roasted meat, environmental pollutants and many products obtained from incomplete combustion9. It has been 
classified by the IARC as a group 1 human carcinogen. B[a]P forms BPDE through a three-step activation pro-
cess catalysed by human cytochrome P450 enzymes, notably CYP1A1 and CYP1B1, and by epoxide hydrolase. 
Approximately 10% of B[a]P is converted to BPDE10. The U.S. population has a daily intake of approximately 
2.2 µg of B[a]P9, which corresponds to about 220 ng BPDE. How much of this is systemically available and reaches 
the target organ is an open question. BPDE is highly carcinogenic and can bind to the exocyclic N2 position of 
guanine to form bulky adducts in a dose-dependent manner11. These bulky adducts are substrates for nucleotide 
excision repair (NER), which protects against the toxic, mutagenic and carcinogenic effects of B[a]P12–14. Data 
on the repair of BPDE adducts and their biological consequences in human endothelial cells are not available.
The wide environmental distribution of B[a]P and the existence of defence systems, including DNA repair, 
encouraged us to question the extent to which the various blood vessel cell types are protected against BPDE and 
the differences in their sensitivity to DNA insults resulting from BPDE exposure. To address these questions, we 
compared the responses of human primary endothelial cells (HUVEC), human primary smooth muscle cells 
(HUASMC) and human primary pericytes (HPC) to BPDE. Furthermore, guided by our previous study, which 
demonstrated that some DNA repair genes show an adaptive upregulation in response to BPDE treatment15, we 
studied the basal expression level of NER proteins/enzymes and the expression of DDB2 and XPC following 
BPDE exposure. Our findings revealed that HUVEC are more sensitive to BPDE than HPC and HUASMC and 
display an unexpected DNA repair-impaired phenotype.
Results
HUVec are more sensitive to BpDe than HUASMc and Hpc. To compare the effect of BPDE on 
vascular cells, we first determined the cytotoxicity of BPDE in primary HUVEC, HUASMC and HPC through 
the MTT viability assay and apoptosis and necrosis measurement through annexin V/PI flow cytometry. The 
viability assay revealed that HUVEC are more sensitive to treatment with BPDE than HUASMC and HPC 
(Fig. 1a). Specifically, a dose of 0.5 µM BPDE reduced the viabilities of HUVEC, HUASMC and HPC to 31, 61 
and 46%, respectively. The apoptosis and necrosis levels after treatment with 1.5 µM (Fig. 1b) and 0.75 µM BPDE 
(Supplementary Material, Fig. S1A) were determined, and the results showed that HUVEC exhibited the highest 
levels of apoptosis and necrosis among the three tested cell types, which was observed at all tested post-exposure 
times. The high sensitivity of HUVEC to BPDE was confirmed by measuring the rate of apoptosis through subG1 
flow cytometry, demonstrating a dramatic difference in apoptosis rate between HUVEC on the one hand and 
HUASMC and HPC on the other (Fig. 1c).
Figure 1. Cytotoxicity induced by BPDE in human vascular cells: HUVEC, HUASMC and HPC. (a) Dose-
dependent effect of BPDE on viability, as measured in the MTT assay 72 h after treatment with BPDE. Viability 
is expressed as percentage relative to the non-treated control. (b) Induction of apoptosis and necrosis following 
1.5 µM BPDE, measured at different times after treatment and determined by annexin V/PI flow cytometry. (c) 
Apoptosis measured by subG1 quantification at different times after treatment with 1.5 µM BPDE. All data are 
the mean ± SEM of at least three independent experiments.
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To ascertain whether the cells undergo premature senescence following BPDE treatment, we measured the 
activity of senescence-associated β-galactosidase. Representative ß-gal stainings are shown in Fig. 2a. The quan-
tification of the results (Fig. 2b) revealed that HUVEC and HUASMC displayed cellular senescence induction 
already after exposure to a low BPDE dose (0.25 µM). The maximum percentages of β-galactosidase-positive 
HUASMC and HUVEC were 67% and 40%, respectively. In contrast, HPC showed only a weak induction of pre-
mature senescence, as demonstrated by the finding that less than 14% displayed β-galactosidase-positive staining. 
We also assessed cell cycle progression and the induction of p21, which is involved in the regulation of senes-
cence, in HUVEC, HUASMC and HPC following BPDE treatment. In all cell types, the G1 fraction declined and 
S and G2/M increased following treatment, indicating S blockage and G2 accumulation (Supplementary Material, 
Fig. S1B). Regarding p21, the highest level was observed in HUASMC, corresponding to the high senescence 
level. It was less induced in HUVEC and marginally only at the highest dose in HPC (Fig. 2c).
Single-strand breaks (SSBs) accumulate in HUVec after exposure to BpDe. To determine the 
genotoxic effects induced by BPDE in the investigated cell types and the repair of BPDE adducts, we used the 
alkaline comet assay to visualize the amount of SSBs in the DNA. It is generally accepted that SSBs, which are 
observed after treatment with genotoxins that induce bulky adducts, represent intermediates of the NER process. 
Thus, during NER, incisions are made 5′ and 3′ from the lesion by the NER endonucleases ERCC1/XPF and 
XPG, respectively. The nucleotide fragment containing the damage is removed, and the resulting gap is sealed by 
repair synthesis and completed by ligation through ligase I and possibly also ligase III. If not immediately sealed, 
these repair intermediates give rise to a reduction in the molecular weight of DNA that can be detected through 
the comet assay. Representative examples of single cells analysed in the alkaline comet assay from the untreated 
control populations and the populations after BPDE treatment are shown in Fig. 3a. The quantification of the 
migrated DNA revealed that HUVEC displayed the highest level of SSBs, and this finding was obtained with all 
doses of BPDE. Compared with primary HUVEC, the other cell populations HUASMC and HPC revealed much 
lower levels of SSBs, particularly after exposure to the lower BPDE doses. Thus, with a dose of 0.5 µM BPDE, 
HUASMC and HPC did not display a significant increase above the control, while in HUVEC the level was signif-
icantly enhanced above the non-treatment control level (p < 0.01) (Fig. 3b).
To assess whether the induction of SSBs and the start of the repair process in HUVEC show differences 
compared with the other cell types, we performed a time course experiment. During the first 7 h of treatment 
with 0.5 µM BPDE, SSB induction and accumulation were clearly observed in HUVEC, whereas the responses 
observed in HUASMC and HPC did not reach the same levels (Fig. 3c). Based on this data, we conclude that in 
Figure 2. Induction of senescence after BPDE treatment in HUVEC, HUASMC and HPC. (a) Cellular 
senescence 96 h after treatment with BPDE visualised by β-galactosidase staining. Representative images 
of β-galactosidase activity (blue stained cells) in non-treated controls and after exposure to 0.75 µM BPDE. 
(b) Amount of senescent cells upon treatment with 0.25, 0.5, 0.75 and 1 µM BPDE. The highest dose of 1 µM 
BPDE could not be evaluated in HUVEC because of strong cytotoxicity induced in these cells. Data shown are 
the mean ± SEM of three independent experiments; a minimum of 1000 cells were counted per experiment. 
Significance was calculated compared to HUVEC. (c) Level of p21 mRNA 24 h after exposure of the indicated 
doses of BPDE. Data are the mean ± SD of three independent experiments, each performed in duplicate.
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Figure 3. Genotoxic effects of BPDE in HUVEC, HUASMC and HPC. (a) Representative images of comets in 
HUVEC, HUASMC and HPC treated with the indicated doses of BPDE and measured 2.5 h after addition of 
BPDE to the medium. (b) Tail intensity determined by the alkaline comet assay as a function of dose of BPDE. 
Cells were fixed and stained 2.5 h after treatment. Each measure point represents the mean of three independent 
experiments ± SEM; a minimum of 50 cells were measured per experiment. (c) Tail intensity in the alkaline 
comet assay after treatment with 0.5 µM BPDE as a function of time. Each measure point represents the mean of 
three independent experiments ± SEM. Cells were embedded in agarose, lysed and subjected to electrophoresis 
as described in Material and Methods. Image analysis and calculation of tail intensities were performed with 
Comet IV software.
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HUVEC, BPDE adducts are recognized and incision occurs. Although this happens, adducts are only incom-
pletely repaired and repair patches are not sealed. Therefore, gaps are left in the DNA resulting in persisting SSBs 
that were detected in the comet assay. In contrast, in HUASMC and HPC, NER occurs nearly to completion, and 
thus, the NER intermediates do not give rise to a substantial accumulation of SSBs.
BpDe-DnA adducts are not completely removed from DnA in HUVec. To substantiate the con-
clusions drawn from the comet assay, we set out to directly determine the removal of BPDE adducts from DNA. 
Using the post-labelling method16, we measured the amount of BPDE adducts per 108 nucleotides over time. The 
results showed that the adduct level remains unchanged in HUVEC, whereas in HUASMC and HPC a decrease in 
the adduct level was observed during a 24 h post-exposure period (Fig. 4; for representative post-labelling images, 
see Supplementary Fig. S2). The data indicate that BPDE adducts are not removed from DNA in HUVEC. We 
should note that the amount of adducts was generally lower in HUASMC and HPC than in HUVEC, which can 
be explained by the higher repair capacity of these cell types, resulting in removal of adducts within the treatment 
and 1 h post-exposure period. Of note, BPDE has a short half-life in medium and thus causes adduct formation 
within minutes after the initiation of treatment. The high adduct levels observed in HUVEC up to 24 h after pulse 
treatment supports the conclusion that HUVEC are defective or, at least, impaired in NER.
expression of neR proteins. To further substantiate the conclusion that the high sensitivity of HUVEC 
to BPDE is due to impaired NER, we compared the expression levels of core NER proteins among HUVEC, 
HUASMC and HPC. A Western blot analysis revealed that the cell types display significant differences in the basal 
NER protein expression (Fig. 5). Thus, the expression of the NER recognition proteins DDB2, XPC and XPA was 
not reduced in HUVEC compared with HUASMC and HPC. However, HUVEC expressed a clearly lower level 
(both basal and after BPDE treatment) of the NER proteins ERCC1, XPF and ligase I, which play key roles in the 
NER pathway, catalysing the incision 5′ to the adduct (the complex ERCC1/XPF acting as NER endonuclease) 
and the ligation of newly synthesized fragments, respectively. Ligase III was reported to be able to replace ligase 
I and supporting NER17, and thus it is interesting to see that ligase III is also expressed at lower level in HUVEC 
than in HUASMC and HPC. The basal expression of the NER polymerase Pol ε was also slightly reduced. This was 
not the case for Pol δ (Supplement Fig. S3). Interestingly, 24 h after treatment with 1 µM BPDE, DDB2 and XPC 
were upregulated at protein level in HUASMC and HPC, respectively, but not in HUVEC. In contrast to this, the 
response of HUVECs to BPDE was characterized by a substantial decline in the DDB2 and XPA levels (Fig. 5a). 
These data might be explained by the high adduct levels observed in HUVEC, which may inhibit transcription 
and thus attenuate the induced response, which is a specific attribute following BPDE treatment as shown pre-
viously with human fibroblasts treated with BPDE doses above 0.75 µM15. This supposition gains support from 
expression studies on mRNA level, where we observed after treatment with 1 µM BPDE lack of induction of 
DDB2 and XPC in HUVEC, while in HUASMC and HPC the level was significantly enhanced (2 up to 4-fold). 
However, with a low dose of 0.5 µM we observed DDB2 and XPC mRNA induction also in HUVEC (Fig. 5b). 
This is compatible with the notion that non-repaired adducts block the BPDE-induced DDB2/XPC response in 
HUVEC, and thus further attenuate the repair of adducts.
increased DnA damage response (DDR) in HUVec after exposure to BpDe. To analyse whether 
the DDR is affected in HUVEC, we determined the protein levels of pCHK1, p53, p53ser15 and p53ser46 in the three 
cell types at several times after BPDE treatment. CHK1 activation was detected 4 and 6 h after exposure, and the 
strongest activation level was observed in HUVEC (Fig. 6a), which agrees with the high BPDE adduct level found 
Figure 4. BPDE-adduct levels in HUVEC, HUASMC and HPC. BPDE adducts (per 108 nucleotides) in 
HUVEC, HUASMC and HPC cells following exposure to 0.5 µM BPDE at different times after treatment. 
Adducts were measured by the 32P-postlabeling method as described in Material and Methods. Data shown are 
the mean of the results obtained in two independent experiments.
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Figure 5. NER protein expression in HUVEC, HUASMC and HPC not treated and treated with BPDE. (a) 
Dose-dependent expression of NER core proteins was analyzed by immuno-detection in total cell extracts 
24 h after exposure to 0, 0.5 and 1 µM BPDE. HSP90 was used as loading control. HUVEC, HUASMC and 
HPC extracts were loaded onto the same blot in each experiment in order to have a direct comparison. The 
same extracts were used in different immunoblots for the indicated proteins. The loading control (HSP90) 
shown in the figure is a representative example. The numbers below each blot for the corresponding repair 
protein indicate the relative expression level, in which HUVEC control was set to 1. Quantitative analysis of 
blot intensity was done with ImageJ and related to the HSP90 control in the same blot. Expression data of a 
representative experiment are shown. (b) mRNA expression of DDB2 and XPC in HUVEC, HUASMC and HPC 
following treatment with 0, 0.5 and 1 µM BPDE. Cells were harvested 24 h after treatment and the expression 
was determined by RT-PCR. Data show the mean ± SD of three independent experiments. The relative mRNA 
expression level of the non-treated control was set to 1.0. The difference to the control was not significant (ns) or 
significant (p = 0.05 *0.01**0.001***).
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in these cells. The activation of p53 (as determined by its stabilization) was clearly detected in all three cell types, 
and we also observed p53 phosphorylation at serine 15 and serine 46. The highest level of activated p53 (p53ser15) 
was consistently observed in HUVEC (the quantified results are shown in Fig. 6b), which supported the notion 
that unrepaired DNA adducts in HUVEC provide a strong and sustained signal for p53ser15 activation.
Discussion
The endothelium, which lines all blood vessels in the body and is supported by the underlying smooth muscle 
cells and pericytes that form the vessel structure, can be considered an organ18. Various studies have attempted 
to define the endothelium as a barrier that protects solid tissues against harmful substances present in blood19. 
A similar well-accepted phenomenon has been ascribed to the brain, where the blood-brain barrier fulfils a pro-
tective function20. Further studies have investigated the protection induced by the endothelium and the barrier 
function of this organ in the cornea21 and the thymus22. A healthy endothelium maintains important cardiovas-
cular functions, e.g., the regulation of blood pressure, coagulation and angiogenesis, and endothelial impairment 
or dysfunction has been shown to be associated with several diseases, e.g., atherosclerosis, diabetes and hyperten-
sion1,18. Therefore, the protection of the endothelium, which constitutes a single-cell layer inside the blood vessels, 
appears to be of utmost importance.
Genotoxic agents, regardless of whether they are endogenously formed or taken up orally or via other routes, 
become systemically available through their presence in blood, and thus, their first contact occurs with the 
endothelium. Because the endothelium is the primary target of systemically available genotoxins, we initially 
hypothesized that endothelial cells are particularly well equipped with DNA repair functions that protect them 
against genotoxic substances present in blood. To prove this working hypothesis, we studied the genotoxic effect 
of BPDE, which is the activated form of benzo[a]pyrene - a widely distributed environmental and tobacco smoke 
genotoxin23 and a well-known carcinogen24. It has previously been shown that benzo[a]pyrene induces DNA 
damage in HUVEC25 and that vascular cells have the capacity to metabolize benzo[a]pyrene via cytochrome 
P4501A1, which is upregulated in vitro in HUVEC25 and SMC26 and in vivo in the rat aortic endothelium27, or via 
cytochrome P4501B1, which was found in mice pericytes28. However, there are no data available regarding the 
cytotoxic response and the repair of BPDE-induced DNA adducts in endothelial cells, particularly in compar-
ison with other vessel cell types. Throughout this study, we used well-defined primary cell pools, measured the 
response of HUVEC to BPDE in comparison with primary smooth muscle cells and primary pericytes. Contrary 
to our expectation, the results showed that HUVEC are more sensitive than HUASMC and HPC to the cytotoxic, 
apoptotic and necrosis-inducing effects of BPDE. However, HUVEC were not more sensitive than HUASMC and 
HPC regarding the end-point cellular senescence, as measured by SA-ß-gal, which was clearly induced in all cell 
types by BPDE.
Figure 6. Level of non-phosphorylated and phosphoryated p53 and pChk1 in HUVEC, HUASMC and HPC. 
(a) The levels of pChk1, p53 and p53ser15/46 were analyzed in Western blots in total cell extracts at various time 
points after treatment with 1 µM BPDE. HSP90 was used as loading control. Immunostainings were performed 
with the same cell extracts that were used for separate blots. Representative blots are shown. (b) Quantification 
of p53ser15 in HUVEC, HUASMC and HPC. Data are related to the level in HUASMC measured 48 h after 
treatment, which was set to 1.
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BPDE forms bulky lesions in DNA by binding to the exocyclic N2-position of guanine, and this adduct is 
subjected to repair through NER29. Our data revealed that the high sensitivity of HUVEC to the cytotoxicity 
of BPDE is due to high and persistent BPDE adduct levels and high amounts of repair intermediates (notably 
SSBs), as demonstrated through the comet assay. The post-labelling experiments confirmed this data and showed 
significantly less repair of BPDE adducts over time. Thus, the adduct level in HUVEC remained constant over a 
24 h post-exposure period, while in HUASMC and HPC there was a decline with about 85 and 60% removal of 
induced adducts, respectively. These findings prompted us to measure the expression levels of key repair proteins. 
An expression-based screening of NER proteins revealed that the levels of ERCC1, XPF and ligase I were clearly 
lower in HUVEC than in HUASMC and HPC. The ERCC1/XPF complex exerts endonuclease activity by cleav-
ing the DNA 5′ from the lesion, while cleavage 3′ from the lesion is catalysed by the endonuclease XPG12. Since 
this protein is expressed in HUVEC, we infer that incisions through XPG surrounding the lesion are made, but 
the repair process is not complete as ERCC1/XPF incisions are not made, resulting in the accumulation of repair 
intermediates (SSBs) in the DNA. The very low level of ligase I further supports the accumulation of repair inter-
mediates. In summary, the low ERCC1/XPF and ligase I levels and incomplete NER observed in HUVEC explains 
the higher level of SSBs detected in HUVEC compared with HUASMC and HPC through the alkaline comet 
assay. This hypothesis also explains the finding that adducts are not removed from DNA. Thus, incisions are made 
by XPG, but the fragment containing the adduct cannot be removed because of lack of ERCC1/XPF mediated 5′ 
incision. In summary, all the observations reported in this manuscript lead to the conclusion that ERCC1/XPF is 
the rate-limiting NER step in HUVEC, preventing the efficient repair of BPDE adducts.
It is very likely that this conclusion also pertains to other bulky adducts induced by a plethora of genotoxins 
the endothelium is exposed to, but this hypothesis has to be confirmed in future studies. Whether impaired NER 
is a specific property of HUVEC or a phenotype that also pertains to other vascular endothelial cells also needs to 
be elucidated. We should note that the established endothelial cell line EA.hy926, which is often used for studies 
on endothelial function, represents only a surrogate cell system because it is a hybrid cell type in which the repair 
functions that are significantly reduced in HUVEC are likely complemented by the cell type used for hybridoma 
formation. Therefore, we used primary HUVEC throughout the study, and we also used pooled primary stocks 
to minimize donor variations.
Tobacco smoke containing benzo[a]pyrene is not only responsible for one third of all cancer cases, but also 
associated with a significant increase in cardiovascular diseases. Thus, it has been estimated that an individual 
who consumes less than five cigarettes per day30, which corresponds to an uptake of 29–190 ng of benzo[a]pyrene 
per day, has 1.5- and 2-fold higher risks for stroke and heart infarct, respectively31, and even living with a smoker 
significantly increases the risks of the non-smoking partner32. Although the causal link between smoking and 
cardiovascular diseases is well accepted, little is known regarding the factors leading to cardiovascular failure. 
Thus, ROS, chemical carcinogens, tumour promoters, particles and nicotine in tobacco smoke have been con-
sidered aetiological factors. A well-established theory claims that the primary reason for cardiovascular diseases 
lies in damage of the endothelium, which causes endothelial cell death followed by a local inflammatory response 
characterized by immune cell recruitment and activation and, in the late stage, plaque formation and rupture33. 
Tobacco smoke contains more than 60 well-defined carcinogens, some of which are highly genotoxic and carcino-
genic34. Despite this knowledge, the most critical factor(s) in tobacco smoke and in the environment responsible 
for endothelial damage following uptake have not been identified. Because our study showed that endothelial 
cells have a decreased ability to repair BPDE-induced DNA adducts and display hypersensitivity to BPDE, it is 
conceivable that BPDE produced from benzo[a]pyrene metabolism in the endothelium causes significant DNA 
damage in this target organ, resulting in cell death and local vascular damage. Because smooth muscle cells and 
pericytes appear to be protected, the cell death limited to the endothelium will not necessarily result in cardiovas-
cular failure, but if the regenerative process fails, it could result in a local lesion that promotes plaque formation.
Endothelial cells are exposed to many chemical stressors and it is important to understand their sensitivities 
and responses to these stress factors. Thus, further studies are warranted to assess the sensitivity and repair capac-
ity of HUVEC compared to other cell types and even cancer cells, since systemically applied genotoxic drugs are 
often used in cancer chemotherapy. The studies might also be extended to radiation in order to better understand 
the radiation response of HUVEC35 and other vascular cell types.
The high cytotoxic response of HUVEC may be considered as a counteractive mechanism to tumor formation. 
Interestingly, hemangiosarcoma resulting from transformed endothelial cells is a highly aggressive, the blood 
vessel invading and rare malignancy in humans36, although it is frequently observed in dogs37. Whether heman-
giosarcoma are more frequent in smokers than in the general population is, to our very best knowledge, not 
known. Nevertheless, it is conceivable that the impaired NER pathway in HUVEC represents a mechanism of 
cancer defense as damaged endothelial cells harbouring carcinogenic adducts are eliminated through apoptosis. 
Nevertheless, the failure of HUVEC to efficiently repair bulky DNA adducts and the related cytotoxic response 
might be a driving force in the genesis of vascular damage and cardiovascular diseases, including blood pressure 
deregulation and atherosclerosis.
Methods
cell culture and chemicals. Studies were performed using pooled primary human umbilical vein endothe-
lial cells (HUVEC, C-12203), human umbilical artery smooth muscle cells (HUASMC, C-12500) and human 
pericytes from placenta (HPC, hPC-PL, C-12980) purchased from PromoCell (Heidelberg, Germany). Cells were 
grown in the corresponding media from PromoCell (Heidelberg, Germany): Endothelial Cell Growth Medium 2 
(Ready-to-use, C-22011), Smooth Muscle Cell Growth Medium 2 (Ready-to-use, C-22062) and Pericyte Growth 
Medium (Ready-to-use, C-28040) with addition of 1% penicillin/streptomycin (Gibco). Cells were routinely cul-
tured under nitrogen atmosphere (7% O2, 5% CO2) and passaged twice a week for a maximum of 15 passages 
using trypsin (Gibco). BPDE was purchased from BIU Biochemical Institute for Environmental Carcinogens, 
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Prof. Dr. G. Grimmer-Stiftung (Grosshansdorf, Germany). BPDE was dissolved in water-free THF/5% trimeth-
ylamine (1 mM) and stored at −80 °C. To avoid hydrolysis of the epoxides, dilutions from the stock solution were 
always prepared fresh immediately before incubation.
Determination of apoptosis/necrosis and metabolic competence. Apoptosis and necrosis induc-
tion was determined by harvesting the cells at different time points after BPDE exposure and performing 
annexin V-FITC/PI double staining combined with flow cytometry. The protocol was essentially as described38. 
The metabolic competence of BPDE-exposed cells was determined by 3-(4,5-dimethyldiazol-2-yl)-2,5-diph
enyltetrazolium bromide (MTT) assay as already described39. In all cases, experiments were repeated at least 
three times, mean values ± standard error of the mean (SEM) are shown.
Determination of senescence. 96 h after exposure to BPDE, cytochemical senescence detection was 
performed with the senescence β-Galactosidase Staining Kit (Cell Signaling) according to the manufacturer’s 
instruction. Quantification occurred as described40.
comet assay. After different time points of exposure to BPDE the alkaline comet assay was performed as 
previously described41.
preparation of protein extracts and western blot analysis. Whole-cell extracts were prepared by 
lysing the cells directly in 1 × sodium dodecyl sulphate-polyacrylamide gel electrophoresis sample buffer and 
subsequent sonification. Antibodies were diluted 1:200–1:1000 in 5% bovine serum albumin (BSA) or 5% milk, 
0.1% Tween-TBS and incubated overnight at 4 °C. Anti-p53, anti-HSP90, anti-DDB2, anti-XPC, anti-XPA, 
anti-ERCC1, anti-XPF, anti-XPG, anti-Pol ε, anti-Pol δ, anti-Lig I and anti-Lig III antibodies were purchased 
from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-pChk1, anti p53ser15 and anti-p53ser46 antibodies were 
obtained from Cell Signaling Technology (Danvers, MA, USA). The protein–antibody complexes were visualized 
by Pierce ECL Western Blotting Substrate (32106, Thermo Fisher).
DnA isolation and 32p-postlabeling of BpDe-adducts. Genomic DNA was isolated by 
phenol-chloroform extraction as previously described42 and quantity and quality was evaluated by 
nano-spectrophotometry (Nanodrop, Thermo Fisgher Sci., Waltham, MA, USA). 32P-postlabeling was performed 
according to previously published procedure16. Briefly, DNA (10 µg) was depolymerized by microccocal nuclease 
and spleen phosphodiesterase (Sigma) and lipophilic adducts extracted by water-saturated butanol. Butanol was 
evaporated by vacuum centrifugation and adducts labelled by T4 polynucleotide kinase (AB Analitica, Padua, 
Italy) using AT-gamma-32P (>6,000 Ci/mmol) (Perkin Elmer, Boston, MA, USA) as 32P donor. 32P-labelled 
adducts were resolved by multi-directional thin layer chromatography on polyethylenimine sheets (Macherey 
Nagel, Duren, Germany) performing washings in sodium phosphate buffers (1 and 1.7 M) and resolution runs 
in urea buffers (8.5 M, pH 8.5 and 3.5). Chromatographic sheets were dried under warm air and analyzed for 
emitted radiation by phosphorimager (32P imager, Packard, Meriden, CT. USA). Radioactive spots were quanti-
fied for emitted radiation, relative adduct labelling index calculated referring to normal nucleotides and results 
expressed as adducts per 108 normal nucleotides. DNA free sample was used as sham control; a standard of 
authentic BPDE-N2-dG adducts (NCI repository, USA) was used as positive reference standard.
RnA isolation, cDnA synthesis and real-time pcR. RNA isolation was performed with the RNA 
extraction kit peq gold RNA kit (peqlab, Erlangen, Germany). RNA concentrations were determined by measur-
ing the absorbance at 260 and 280 nm. 1 µg of RNA was used for cDNA synthesis with the Verso cDNA Synthesis 
Kit (Thermo Fisher Scientific, Darmstadt, Germany). qPCR was performed by CFX96 Real-Time PCR Detection 
System (Bio-Rad Laboratories GmbH, Hercules, CA, USA). Gapdh and Actb served as internal housekeeping 
genes. Primer sequences are shown in Supplementary Table 1.
Statistics and ethic statement. Data were statistically analyzed using Student’s unpaired two-sample 
t-test on the basis of a difference between sample means. Calculations were performed using the GraphPad Prism 
software (*P < 0.05, **P < 0.005, ***P < 0.0005). All methods were carried out in accordance with relevant 
guidelines and regulations. Primary cell stocks obtained from PromoCell (Heidelberg, Germany) were approved 
and generated according to the “German Federal Data Protection Act”.
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